In the HIMALAYA trial of 305 people with ALS in 13 countries, the RIPK1 inhibitor SAR443820 did not slow functional decline over 24 weeks and caused more liver enzyme increases than placebo.
Pooling double-blind trials in adults with depression, escitalopram and amitriptyline lengthened the QTc interval, a heart rhythm measure, more than placebo. Antidepressants were not linked to more early major heart events.
In a cohort study published Oct. 27, 2026, in Diabetes Care, people 75 and older with type 2 diabetes who started an SGLT2 inhibitor had lower risks of acute kidney injury and…
